Fig. 4

Tumor targeting of RGD-modified nanoparticles. a-b Analysis of the cellular uptake of MOF-L and MOF-LR by flow cytometry (n = 3). c The biodistribution of MOF-L and MOF-LR in vivo. d Average fluorescence intensity of DiR in the tumor tissue is higher over time in the MOF-LR group than that in the MOF-L group. * p < 0.05, ** p < 0.01